



BioAegis Therapeutics Presents to Investors at the MACRO Trends Conference in Antwerp, Belgium

BOSTON, MA and MORRISTOWN, NJ, (BIOAEGIS THERAPEUTICS) April 25, 2017 BioAegis Therapeutics Inc., a privately held biotechnology company commercializing plasma gelsolin (pGSN), presented at the **MACRO Trends Conference** in Antwerp, Belgium. Presenting for the company was Mr. Steven Cordovano Co-Founder and Vice President of Investor Relations.

About MACRO Trends

MACRO Trends is a Dutch Investment advisory firm centered around a regularly published magazine edited by Brecht Arnaert, a monetary expert at the Rey Juan Carlos University in Madrid and has been the editor-in-chief of MACRO Trends since November 2013. The magazine covers a wide range of topics including the outlook for international currencies, gold, crypto currencies and special situation equities. It sponsors several research-focused conferences per year attended by a diverse group of European investors.

About Plasma Gelsolin

The highly abundant endogenous plasma protein, pGSN, harnesses the innate immune system to modulate the inflammatory response as well as boost the capacity of immune cells to fight infection. Decreased plasma gelsolin levels at presentation are found in patients with diverse infectious and non-infectious inflammatory diseases, who are at high risk for developing serious complications.

Based on recent breakthrough findings in studies conducted at the TH Chan Harvard School of Public Health, BioAegis is pursuing Phase 2 studies in severe community acquired pneumonia.

Severe Community Acquired Pneumonia is a leading cause of death in the US and around the world. The adverse outcomes, including organ failure and mortality, generate enormous cost to the health care system. As a result of organ damage, survivors often require ongoing care after being discharged from the ICU due to lingering neurocognitive and functional disabilities. This puts an enormous incremental strain on the health care system. Plasma gelsolin repletion therapy is expected to reduce these adverse outcomes as well as the costs associated with severe disease.

About BioAegis Therapeutics

BioAegis Therapeutics was founded by a group of highly experienced pharmaceutical and financial executives. Its mission is to harness the body's innate immune system to address serious outcomes in diseases driven by inflammation.

This press release contains express or implied forward-looking statements, which are based on current expectations of management. These statements relate to, among other things, our expectations regarding management's plans, objectives, and strategies. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. BioAegis assumes no obligation to update any forward-looking statements appearing in this press release in the event of changing circumstances or otherwise, and such statements are current only as of the date they are made.

For further information:

Steven Cordovano, 203-952-6373

Email: scordovano@bioagistx.com

www.bioagistx.com